Growth hormone therapy and the risk of tumor recurrence after brain tumor treatment in children

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 9, 2010, Pages 935-942

  Rohrer, Tilman R ^a   Langer, Thorsten ^b,c   Grabenbauer, Gerhard G ^b,d   Buchfelder, Michael ^b,d   Glowatzki, Matthias ^e   Dörr, Helmuth G ^b,c  

^a Department of Pediatrics and Adolescent Medicine   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Hospital for Children and Adolescents   (Germany)

^d Department of Radiotherapy ^*  (Germany)

^e SPSS GmbH Software   (Germany)

Author keywords

Childhood brain tumor; Craniopharyngioma; Ependymoma; GH replacement therapy; Medulloblastoma; Pediatric brain tumor recurrence; Relapse risk

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE;

ADOLESCENT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CRANIOPHARYNGIOMA; EPENDYMOMA; FEMALE; HORMONAL THERAPY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; TUMOR RECURRENCE;

EID: 77958541304     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2010.150     Document Type: Article

References (24)

1. Kaatsch P, Rickert CH, Kühl J, Schüz J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer 2001; 92: 3155-3164. (Pubitemid 33136212)
2. Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am 1997; 44: 489-503.
3. Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 2003; 40:224-229.
4. Gleeson HK, Stoeter R, Ogilvy-Stuart AL, Gattamaneni HR, Brennan BM, Shalet SM. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 2003; 88: 3682-3689.
5. Arslanian SA, Becker DJ, Lee PA, Drash AL, Foley TPJ. Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism. Am J Dis Child 1985; 139: 347-350.
6. Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy. Horm Res 1997; 48 Suppl 4: 29-32.
7. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152.
8. Ezzat S, Melmed S. Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991; 72: 245-249.
9. Clayton PE, Shalet SM, Gattamaneni HR, Price DA. Does growth hormone cause relapse of brain tumours? Lancet 1987; 1:711-713.
10. Ogilvy-Stuart AL, Ryder WD, Gattamaneni HR, Clayton PE, Shalet SM. Growth hormone and tumour recurrence. BMJ 1992; 304: 1601-1605.
11. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WD, Brada M, Hayward RD, Brook CG, Hindmarsh PC, Shalet SM. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000; 85: 4444-4449.
12. Buyukpamukcu M, Varan A, Yazici N, Akalan N, Soylemezoglu F, Zorlu F, Akyuz C, Kutluk MT. Second malignant neoplasms following the treatment of brain tumors in children. J Child Neurol 2006; 21: 433-436.
13. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91: 3494-3498.
14. Darendeliler F, Karagiannis G, Wilton P, Ranke MB, Albertsson-Wikland K, Price DA. Recurrence of brain tumours in patients treated with growth hormone: Analysis of KIGS (Pfizer International Growth Database). Acta Paediatrica 2006; 95: 1284-1290.
15. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002; 87: 3136-3141.
16. Clayton PE, Price DA, Shalet SM, Gattamaneni HR. Craniopharyngioma recurrence and growth hormone therapy. Lancet 1988; March 19: 642-642.
17. Karavitaki N, Warner JT, Marland A, Shine B, Ryan F, Arnold J, Turner HE, Wass JA. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 2006; 64: 556-560.
18. Moshang T Jr, Rundle AC, Graves DA, Nickas J, Johanson A, Meadows A. Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr 1996; 128: S4-S7. (Pubitemid 26145973)
19. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93: 618-629. (Pubitemid 32409629)
20. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999; 90: 237-250.
21. Karavitaki N, Brufani C, Warner JT, Adams CB, Richards P, Ansorge O, Shine B, Turner HE, Wass JA. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62: 397-409.
22. Kim SK, Wang KC, Shin SH, Choe G, Chi JG, Cho BK. Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factor. Childs Nerv Syst 2001; 17: 531-536. (Pubitemid 32842709)
23. Packer RJ, Boyett JM, Janss AJ, Stavrou T, Kun L, Wisoff J, Russo C, Geyer R, Phillips P, Kieran M, Greenberg M, Goldman S, Hyder D, Heideman R, Jones-Wallace D, August GP, Smith SH, Moshang T. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001; 19: 480-487.
24. Sklar C. Paying the price for cure-treating cancer survivors with growth hormone. J Clin Endocrinol Metab 2000; 85: 4441-4443.